NanoString Technologies, Inc. (NSTG)
(Delayed Data from NSDQ)
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the continuous rollout of Alinity, Abbott's suite of diagnostic instruments.
Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business
by Zacks Equity Research
Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.
Does NanoString (NSTG) Have the Potential to Rally 117% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for NanoString (NSTG) points to an 116.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in NanoString (NSTG)? Wall Street Analysts Think 122%
by Zacks Equity Research
The mean of analysts' price targets for NanoString (NSTG) points to a 121.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does NanoString (NSTG) Have the Potential to Rally 104% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 103.7% in NanoString (NSTG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NanoString Technologies (NSTG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -30.19% and -0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -7.14% and 2.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -6.90% and 5.19%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q1 Earnings on May 10: MRVI, TGTX & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
NanoString Technologies (NSTG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -12.77% and 1.72%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NanoString Technologies (NSTG) Q4 Earnings Expected to Decline
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of 8.20% and 5.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 22nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for August 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
NanoString Technologies (NSTG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -28.57% and 40.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Will NanoString Technologies (NSTG) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
NanoString (NSTG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NanoString Technologies (NSTG) Surges: Stock Moves 10.3% Higher
by Zacks Equity Research
NanoString Technologies (NSTG) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
NanoString Technologies (NSTG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -34.69% and 7.86%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why NanoString Technologies (NSTG) Stock Might be a Great Pick
by Zacks Equity Research
NanoString Technologies (NSTG) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Quidel (QDEL) Looks Good: Stock Adds 10.8% in Session
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for March 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 3rd